Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients

AstraZeneca's new antibody has been given a significant reduction in the risk of developing severe Covid-19 or death in patients with mild-to-moderate symptomatic COVID-19 - according to the British Medical Journal (BMJ) .

Source: investegate.co.uk
Published on 2021-10-11